{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.6","value":"2.8"}]}],"title":"Infants and Toddlers (age<2 years old; n=2)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"95.7","value":"6.1"}]}],"title":"Children (age>=2 and <12 years old; n=40)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"66.8","value":"3.8"}]}],"title":"Adolescents (age>=12 and <18 years old; n=28)"},{"categories":[{"measurements":[{"comment":"Due to insufficient number of participants in this age group (only 1 participant), CV% could not be calculated.","groupId":"OG000","spread":"NA","value":"2.2"}]}],"title":"Above 18 Years (n=1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"98.1","value":"4.9"}]}],"title":"Total (n=71)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"description":"PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC\\[0-T\\] is the area under the plasma concentration-time curve from time zero to time of last quantifiable concentration, normalized by dasatinib dose level.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Stratum 1 (Ph+ CP-CML): Participants with imatinib-resistant Ph+ CML in CP; Stratum 2/3 (PH+ ALL OR AP/BP-CML): Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in AP, or in MBP, or in LBP; or relapsed or refractory Ph+ ALL after imatinib use; or second or subsequent relapse of Ph+ AML; Stratum 4 (PH- ALL/AML): Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Strata 1, 2/3, and 4: 60 mg/m\\^2 starting dose; 80 mg/m\\^2 escalated/dose level 2; Stratum 4: 100 mg/m\\^2 escalated/dose level 3 and 120 mg/m\\^2 escalated/dose level 4. QD, as long as clinical benefit was observed.","id":"OG000","title":"Dasatinib 60 mg/m^2 QD Starting Dose"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All treated participants with plasma samples available. Each participant could have 1, 2, or 3 plasma PK profiles sampled, depending on the number of times the dose of dasatinib was escalated. n=number of PK parameters included.","reportingStatus":"POSTED","timeFrame":"During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).","title":"Dasatinib Plasma Pharmacokinetic Parameter: Dose Normalized Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-T]) by Age Group","type":"SECONDARY","unitOfMeasure":"ng.h/mL/mg/m^2"}